Literature DB >> 15879301

Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans.

Katariina Oörni1, Pirjo Posio, Mika Ala-Korpela, Matti Jauhiainen, Petri T Kovanen.   

Abstract

OBJECTIVE: Infiltration of low-density lipoprotein (LDL) into subendothelial space is an early step in atherosclerosis. In addition to LDL particles, small very low-density lipoprotein (sVLDL) and intermediate-density lipoprotein (IDL) particles are also able to enter the arterial intima and be retained within the subendothelial extracellular matrix. Here we compared how proteolysis with alpha-chymotrypsin and phospholipid hydrolysis with phospholipase A2 or sphingomyelinase (SMase) of sVLDL, IDL, and LDL particles can influence their aggregation, fusion, and binding to human arterial proteoglycans in vitro. METHODS AND
RESULTS: In each of the 3 lipoprotein classes, the particles became only slightly aggregated with alpha-chymotrypsin or phospholipase A2. However, the particles strongly aggregated when treated with SMase. The aggregated/fused particles were found to bind to proteoglycans in proteoglycan affinity chromatography more tightly than the native-sized counterparts. In addition, in a microtiter well assay, the binding of SMase-treated lipoproteins was enhanced: the amounts of proteoglycan-bound SMase-treated LDL, IDL, and sVLDL were 4-, 5-, and 20-fold higher, respectively, than the amounts of proteoglycan-bound native lipoproteins.
CONCLUSIONS: These results imply a specific role for SMase as an sVLDL- and IDL-modifying enzyme and also suggest a novel mechanism of lipid accumulation in atherogenesis, namely enhanced retention of atherogenic triglyceride-rich lipoprotein particles in intimal areas expressing extracellular SMase activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879301     DOI: 10.1161/01.ATV.0000168912.42941.60

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  21 in total

1.  Apolipoprotein A-I mimetic peptide 4F blocks sphingomyelinase-induced LDL aggregation.

Authors:  Su Duy Nguyen; Matti Javanainen; Sami Rissanen; Hongxia Zhao; Jenni Huusko; Annukka M Kivelä; Seppo Ylä-Herttuala; Mohamad Navab; Alan M Fogelman; Ilpo Vattulainen; Petri T Kovanen; Katariina Öörni
Journal:  J Lipid Res       Date:  2015-04-10       Impact factor: 5.922

Review 2.  Glycosyltransferases, glycosylation and atherosclerosis.

Authors:  Qianghong Pu; Chao Yu
Journal:  Glycoconj J       Date:  2014-10-08       Impact factor: 2.916

3.  Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH.

Authors:  Mia Sneck; Su Duy Nguyen; Tero Pihlajamaa; Gebrenegus Yohannes; Marja-Liisa Riekkola; Ross Milne; Petri T Kovanen; Katariina Oörni
Journal:  J Lipid Res       Date:  2012-06-20       Impact factor: 5.922

4.  Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression.

Authors:  Cecilia M Devlin; Andrew R Leventhal; George Kuriakose; Edward H Schuchman; Kevin Jon Williams; Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

5.  Control of autophagy maturation by acid sphingomyelinase in mouse coronary arterial smooth muscle cells: protective role in atherosclerosis.

Authors:  Xiang Li; Ming Xu; Ashley L Pitzer; Min Xia; Krishna M Boini; Pin-Lan Li; Yang Zhang
Journal:  J Mol Med (Berl)       Date:  2014-01-25       Impact factor: 4.599

6.  Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL.

Authors:  Boris B Boyanovsky; Preetha Shridas; Michael Simons; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2008-12-03       Impact factor: 5.922

7.  Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a novel nucleotide phosphodiesterase regulated by cholesterol in human macrophages.

Authors:  Mathew Traini; Carmel M Quinn; Cecilia Sandoval; Erik Johansson; Kate Schroder; Maaike Kockx; Peter J Meikle; Wendy Jessup; Leonard Kritharides
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

8.  Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control.

Authors:  Meihui Pan; Vatsala Maitin; Sajesh Parathath; Ursula Andreo; Sharron X Lin; Carly St Germain; Zemin Yao; Frederick R Maxfield; Kevin Jon Williams; Edward A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

Review 9.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.